Natsumi Fukuhara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natsumi Fukuhara has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Katsuyuki Hoshina
Department of Vascular Surgery, The University of Tokyo, Tokyo, Japan
2 shared publications F. Ikuta
Department of Internal Medicine (Dr. Tanno), National Sanatorium Nishi-Ojiya Hospital, Ojiya; the Departments of Neurology (Drs. Tanno, Yoneda, Tanaka, Kondo, Hozumi. and Tsuji) and Pathology (Drs. Wakabayashi, Yamada, and Ikuta), Brain Research Institute, Niigata University, Niigata; and the Department of Neurology (Dr. Fukuhara), National Saigata Hospital, Oogata-machi, Japan
1 shared publication- Isao Hozumi
Laboratory of Medical Therapeutics and Molecular Therapeutics, Department Biomedical Pharmaceutics, Gifu Pharmaceutical University, Gifu City, Japan
1 shared publication K. Wakabayashi
Department of Internal Medicine (Dr. Tanno), National Sanatorium Nishi-Ojiya Hospital, Ojiya; the Departments of Neurology (Drs. Tanno, Yoneda, Tanaka, Kondo, Hozumi. and Tsuji) and Pathology (Drs. Wakabayashi, Yamada, and Ikuta), Brain Research Institute, Niigata University, Niigata; and the Department of Neurology (Dr. Fukuhara), National Saigata Hospital, Oogata-machi, Japan
1 shared publicationKazuhiro Miyahara
Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
1 shared publication- Kazuyoshi Matsubara
Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 24 February 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 808383
Specific Features of Patients Under 40 Years Old With Small-to-Medium-Sized Arterial Deterioration
Background: Arterial deterioration is mostly caused by atherosclerosis, which progresses with age. However, we have observed serious backgrounds or etiologies in younger patients with non-atherosclerotic diseases and deterioration of small-to-medium-sized arterial lesions. Therefore, we aimed to identify the specific features of patients aged P = 0.011). Furthermore, the data analysis of patients with multiple arterial lesions (≥3) revealed that the younger population tended to have more specific backgrounds or etiologies, notably Ehlers-Danlos syndrome and Behçet's disease. There were no differences in the all-cause mortality and cardiovascular disease-related mortality between patients aged P = 0.89 and 0.29, respectively).Conclusions: Over 50% of patients aged <40 years with deterioration of small-to-medium-sized arteries had non-atherosclerotic, specific clinical backgrounds or etiologies, including genetic and inflammatory diseases. In addition, they exhibited more arterial lesions than older patients.
- 24 February 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 808383
Open AccessSpecific Features of Patients Under 40 Years Old With Small-to-Medium-Sized Arterial Deterioration
Background: Arterial deterioration is mostly caused by atherosclerosis, which progresses with age. However, we have observed serious backgrounds or etiologies in younger patients with non-atherosclerotic diseases and deterioration of small-to-medium-sized arterial lesions. Therefore, we aimed to identify the specific features of patients aged P = 0.011). Furthermore, the data analysis of patients with multiple arterial lesions (≥3) revealed that the younger population tended to have more specific backgrounds or etiologies, notably Ehlers-Danlos syndrome and Behçet's disease. There were no differences in the all-cause mortality and cardiovascular disease-related mortality between patients aged P = 0.89 and 0.29, respectively).Conclusions: Over 50% of patients aged <40 years with deterioration of small-to-medium-sized arteries had non-atherosclerotic, specific clinical backgrounds or etiologies, including genetic and inflammatory diseases. In addition, they exhibited more arterial lesions than older patients.
- Open Access
- 18 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (22) , 8702
Efficient Suppression of Abdominal Aortic Aneurysm Expansion in Rats through Systemic Administration of Statin-Loaded Nanomedicine
Abdominal aortic aneurysm (AAA) is a life-threatening disease. However, no systemically injectable drug has been approved for AAA treatment due to low bioavailability. Polymeric micelles are nanomedicines that have the potential to improve therapeutic efficacy by selectively delivering drugs into disease sites, and research has mainly focused on cancer treatments. Here, we developed a statin-loaded polymeric micelle to treat AAAs in rat models. The micelle showed medicinal efficacy by preventing aortic aneurysm expansion in a dose-dependent manner. Furthermore, the micelle-injected group showed decreased macrophage infiltration and decreased matrix metalloproteinase-9 activity in cases of AAA.
- 18 November 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (22) , 8702
Open AccessEfficient Suppression of Abdominal Aortic Aneurysm Expansion in Rats through Systemic Administration of Statin-Loaded Nanomedicine
Abdominal aortic aneurysm (AAA) is a life-threatening disease. However, no systemically injectable drug has been approved for AAA treatment due to low bioavailability. Polymeric micelles are nanomedicines that have the potential to improve therapeutic efficacy by selectively delivering drugs into disease sites, and research has mainly focused on cancer treatments. Here, we developed a statin-loaded polymeric micelle to treat AAAs in rat models. The micelle showed medicinal efficacy by preventing aortic aneurysm expansion in a dose-dependent manner. Furthermore, the micelle-injected group showed decreased macrophage infiltration and decreased matrix metalloproteinase-9 activity in cases of AAA.
- 1 June 1993
- Published by Wolters Kluwer Health in Neurology
- Vol. 43 (6) , 1198
Uniform tissue distribution of tRNA Lys mutation in mitochondrial DNA in MERRF patients
We documented the presence of a point mutation in the tRNA(Lys) gene of mitochondrial DNA (mtDNA) in various postmortem tissues from two patients with myoclonus epilepsy associated with ragged-red fibers (MERRF). The percentages of the mutant mtDNA were similar (93 to 99%) in both clinically affected and unaffected tissues, suggesting that preferential clinical involvement of certain tissues in MERRF is based not only on the variation of distribution of the mutant mtDNA, but also on other factors such as differences in the threshold in various CNS regions and organs.
- 1 June 1993
- Published by Wolters Kluwer Health in Neurology
- Vol. 43 (6) , 1198
Uniform tissue distribution of tRNA Lys mutation in mitochondrial DNA in MERRF patients
We documented the presence of a point mutation in the tRNA(Lys) gene of mitochondrial DNA (mtDNA) in various postmortem tissues from two patients with myoclonus epilepsy associated with ragged-red fibers (MERRF). The percentages of the mutant mtDNA were similar (93 to 99%) in both clinically affected and unaffected tissues, suggesting that preferential clinical involvement of certain tissues in MERRF is based not only on the variation of distribution of the mutant mtDNA, but also on other factors such as differences in the threshold in various CNS regions and organs.